Mesoblast (MESO) Gross Profit (2016 - 2023)
Mesoblast recorded quarterly Gross Profit of $13.6 million in Q2 2023, up 111.23% quarter-over-quarter from -$121.5 million in Q1 2023, and up 254.76% year-over-year from $3.8 million in Q2 2022.
Mesoblast's Gross Profit history runs 8 years deep, the most recent figure standing at $13.6 million for Q2 2023.
- In Q2 2023, Gross Profit rose 254.76% year-over-year to $13.6 million; the TTM figure through Jun 2023 stood at -$444.3 million (down 41.3% YoY), while the FY2025 annual figure was $12.1 million, changed N/A from the prior year.
- Gross Profit came in at $13.6 million for Q2 2023 at Mesoblast, up from -$121.5 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $341.6 million in Q2 2021 to a low of -$250.8 million in Q3 2022.
- A 5-year average of -$28.8 million and a median of -$31.2 million in 2019 frame the typical range for Gross Profit.
- Across the five-year window, Gross Profit surged 46937.01% in 2020 and slumped 4208.34% in 2021, its largest moves.
- Mesoblast's Gross Profit stood at -$84.4 million in 2019, then jumped by 95.01% to -$4.2 million in 2020, then plunged by 4208.34% to -$181.3 million in 2021, then surged by 52.78% to -$85.6 million in 2022, then soared by 115.93% to $13.6 million in 2023.
- According to Business Quant data, Gross Profit over the past three periods registered $13.6 million, -$121.5 million, and -$85.6 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 13.64 Mn |
| Jun 30, 2023 | 13.64 Mn |
| Mar 31, 2023 | -121.49 Mn |
| Mar 31, 2023 | -121.49 Mn |
| Dec 31, 2022 | -85.63 Mn |
| Dec 31, 2022 | -85.63 Mn |
| Sep 30, 2022 | -250.85 Mn |
| Sep 30, 2022 | -250.85 Mn |
| Jun 30, 2022 | -8.82 Mn |
| Jun 30, 2022 | -8.82 Mn |
| Mar 31, 2022 | -3.58 Mn |
| Mar 31, 2022 | -3.58 Mn |
| Dec 31, 2021 | -181.34 Mn |
| Dec 31, 2021 | -181.34 Mn |
| Sep 30, 2021 | -120.73 Mn |
| Sep 30, 2021 | -120.73 Mn |
| Jun 30, 2021 | 341.65 Mn |
| Jun 30, 2021 | 341.65 Mn |
| Mar 31, 2021 | -5.24 Mn |
| Mar 31, 2021 | -5.24 Mn |
| Dec 31, 2020 | -4.21 Mn |
| Dec 31, 2020 | -4.21 Mn |
| Sep 30, 2020 | -10.62 Mn |
| Sep 30, 2020 | -10.62 Mn |
| Jun 30, 2020 | 225.29 Mn |
| Jun 30, 2020 | 225.29 Mn |
| Mar 31, 2020 | -82.37 Mn |
| Mar 31, 2020 | -82.37 Mn |
| Dec 31, 2019 | -84.37 Mn |
| Dec 31, 2019 | -84.37 Mn |
| Sep 30, 2019 | -51.71 Mn |
| Sep 30, 2019 | -51.71 Mn |
| Jun 30, 2019 | -481,000.00 |
| Jun 30, 2019 | -481,000.00 |
| Mar 31, 2019 | -88.42 Mn |
| Mar 31, 2019 | -88.42 Mn |
| Dec 31, 2018 | -89.42 Mn |
| Dec 31, 2018 | -89.42 Mn |
| Sep 30, 2018 | -63.60 Mn |
| Sep 30, 2018 | -63.60 Mn |
| Jun 30, 2018 | -421,000.00 |
| Jun 30, 2018 | -421,000.00 |
| Mar 31, 2018 | -95.26 Mn |
| Mar 31, 2018 | -95.26 Mn |
| Dec 31, 2017 | -155.97 Mn |
| Dec 31, 2017 | -155.97 Mn |
| Sep 30, 2017 | 297,000.00 |
| Sep 30, 2017 | 297,000.00 |
| Jun 30, 2017 | -584,000.00 |
| Jun 30, 2017 | -584,000.00 |
| Mar 31, 2017 | -2.93 Mn |
| Mar 31, 2017 | -2.93 Mn |
| Dec 31, 2016 | -3.36 Mn |
| Dec 31, 2016 | -3.36 Mn |
| Sep 30, 2016 | -3.08 Mn |
| Sep 30, 2016 | -3.08 Mn |
| Jun 30, 2016 | 19.16 Mn |
| Jun 30, 2016 | 19.16 Mn |
| Mar 31, 2016 | -3.87 Mn |
| Mar 31, 2016 | -3.87 Mn |